While guadecitabine sensitizes pancreatic cancer cells to chemotherapeutic agents [29], there is only one phase I study evaluating the anti-tumor effect of DNMT inhibitor on pancreatic cancer [30]. This evidence concerns the gene DNMT1 and neoplasm.